XSHE
000597
Market cap1.02bUSD
Oct 09, Last price
4.91CNY
1D
2.72%
1Q
8.87%
Jan 2017
9.01%
Name
Northeast Pharmaceutical Group Co
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Northeast Pharmaceutical Group Co., Ltd., established in 1993 and headquartered in Shenyang, China, is a key manufacturer and supplier of active pharmaceutical ingredients (APIs) derived from both chemical synthesis and bio-fermentation. The company also develops and distributes various medicinal and micro-ecological preparation products within China. Its broad portfolio includes nutritional supplements such as Vitamin C and L-Carnitine, as well as specific APIs like fosfomycin and anti-AIDS compounds. Furthermore, it produces chemical goods, including pharmaceutical intermediates and chiral separation reagents. Beyond these, Northeast Pharmaceutical manufactures finished drugs for diverse applications, including digestives, narcotic medicines, and treatments for cardiovascular and cerebrovascular conditions. The group also maintains a significant presence in the medical distribution sector.
Key people
Yong Ji
Vice Chairman of the Board · since 2013
Haijun Wei
Chairman of the Board, General Manager, Acting Secretary of the Board · since 2013
Yuanhang Wang
Deputy General Manager · since 2011
Zhanwu Xie
Deputy General Manager · since 2010
Wenfeng Yang
Deputy General Manager · since 2020
Lidong Zhang
Chief Financial Officer, Deputy General Manager · since 2019
Aiguo Jiang
Director · since 2019
Kai Zhou
Director · since 2005
Haixin Yao
Independent Director · since 2013
Shufang Zhang
Independent Director · since 2013
Headquarters & legal address
沈阳经济技术开发区昆明湖街
沈阳市, LN 100000
CN
沈阳市, LN 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||